Letter to the Editor

  • HOME
  • ARTICLE CATEGORY
  • Letter to the Editor
Letter to the Editor
Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023
Donghee Kim, Rohit Loomba, Aijaz Ahmed
Clin Mol Hepatol. 2025;31(3):e235-e238.   Published online December 30, 2024
View: 1822   Download: 193  Crossref: 3
What is new in the 2024 Chinese guidelines for fatty liver disease?
Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan
Clin Mol Hepatol. 2025;31(3):e239-e246.   Published online January 21, 2025
View: 922   Download: 68
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Chi-Kuei Hsu, Po-Yu Huang, Chih-Cheng Lai
Clin Mol Hepatol. 2025;31(3):e247-e248.   Published online February 6, 2025
View: 759   Download: 37
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou
Clin Mol Hepatol. 2025;31(3):e252-e253.   Published online February 26, 2025
View: 1112   Download: 62
Letter to the editor on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
Meng-Che Wu, Hui-Chin Chang, Yi-Sheng Jhang, Shuo-Yan Gau
Clin Mol Hepatol. 2025;31(1):e13-e14.   Published online September 2, 2024
View: 1456   Download: 108  Crossref: 1
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen
Clin Mol Hepatol. 2025;31(1):e35-e38.   Published online September 20, 2024
View: 1402   Download: 75  Web of Science: 1  Crossref: 1
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu
Clin Mol Hepatol. 2025;31(1):e31-e34.   Published online September 20, 2024
View: 1477   Download: 112  Web of Science: 1  Crossref: 2
Accountability in AI medicine: A critical appraisal of ChatGPT in patient self-management and screening
Jiawen Wang, Tian Xia
Clin Mol Hepatol. 2025;31(1):e1-e2.   Published online September 26, 2024
View: 1184   Download: 50
Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li
Clin Mol Hepatol. 2025;31(1):e3-e4.   Published online October 7, 2024
View: 1253   Download: 52  Crossref: 1
2060
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
Donghee Kim, Won Kim, Aijaz Ahmed
Clin Mol Hepatol. 2025;31(1):e5-e7.   Published online October 8, 2024
View: 1178   Download: 45  Web of Science: 1  Crossref: 1
Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma
Xiping Shen, Ji Wu
Clin Mol Hepatol. 2025;31(1):e17-e18.   Published online October 11, 2024
View: 1238   Download: 51  Crossref: 1
Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”
Wei Feng, Qile Wang, Qingwang Ye
Clin Mol Hepatol. 2025;31(1):e21-e22.   Published online October 11, 2024
View: 1259   Download: 30  Web of Science: 1
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs
Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau
Clin Mol Hepatol. 2025;31(1):e19-e20.   Published online October 17, 2024
View: 1041   Download: 35
2077
Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China
Lei Cai, Chao Li, Li-Yang Sun, Yong-Kang Diao, Ming-Da Wang, Tian Yang
Clin Mol Hepatol. 2025;31(1):e39-e43.   Published online October 23, 2024
View: 1149   Download: 58  Crossref: 1
Insights on risk score development: Considerations for early-stage hepatocellular carcinoma models
Zhanna Zhang, Gongqiang Wu
Clin Mol Hepatol. 2025;31(1):e8-e9.   Published online November 6, 2024
View: 1104   Download: 42  Web of Science: 1  Crossref: 1
Grading severity of microvascular invasion in hepatocellular carcinoma: More details, more significance
Xiu-Ping Zhang, Fei-Fan Wu, Tian-Chen Zhang, Zhen-Qi Li, Ming-Gen Hu, Rong Liu
Clin Mol Hepatol. 2025;31(1):e10-e12.   Published online November 26, 2024
View: 1594   Download: 61
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus
Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng
Clin Mol Hepatol. 2025;31(1):e23-e24.   Published online November 26, 2024
View: 1016   Download: 25
The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread
Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang
Clin Mol Hepatol. 2025;31(1):e25-e26.   Published online December 10, 2024
View: 1175   Download: 43  Crossref: 1
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Clin Mol Hepatol. 2024;30(4):982-986.   Published online August 27, 2024
View: 2025   Download: 67  Web of Science: 1  Crossref: 1

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 6338
TOTAL : 2920392
Close layer